Benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonist of retinoid-related orphan receptor gamma (RORt) are described. A pharmaceutical composition including such compounds, as well as the use thereof for the topical and/or oral treatment of RORt receptor-medicated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.

The present invention relates to novel compounds of general formula (I) wherein the groups X, and R.sup.1 to R.sup.4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

##STR00001##

The present invention relates to novel compounds of general formula (I) wherein the groups X, and R.sup.1 to R.sup.4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

##STR00001##

The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): ##STR00001##
comprising treating a compound of Formula (I): ##STR00002##
with a transition metal catalyst and under alkylation conditions as valence and stability permit.

The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): ##STR00001##
comprising treating a compound of Formula (I): ##STR00002##
with a transition metal catalyst and under alkylation conditions as valence and stability permit.

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

The present invention provides a spontaneous orientation aid for a liquid crystal composition, containing one kind or two or more kinds of a compound having a partial structure represented by the general formula (i), wherein Z.sup.i1 represents a single bond, etc.; A.sup.i1 represents a divalent 6-membered aromatic group, etc.; m.sup.i1 represents an integer of 1 to 5; and K.sup.i1 represents a structure represented by any of the following formulae (K-1) to (K-8), wherein W.sup.K1 represents a methine group, etc.; X.sup.K1 and Y.sup.K1 each represent CH.sub.2, etc.; Z.sup.K1 represents an oxygen atom, etc.; and U.sup.K1, V.sup.K1, and S.sup.K1 each represent a methine group, etc.:

##STR00001##

The present invention provides a spontaneous orientation aid for a liquid crystal composition, containing one kind or two or more kinds of a compound having a partial structure represented by the general formula (i), wherein Z.sup.i1 represents a single bond, etc.; A.sup.i1 represents a divalent 6-membered aromatic group, etc.; m.sup.i1 represents an integer of 1 to 5; and K.sup.i1 represents a structure represented by any of the following formulae (K-1) to (K-8), wherein W.sup.K1 represents a methine group, etc.; X.sup.K1 and Y.sup.K1 each represent CH.sub.2, etc.; Z.sup.K1 represents an oxygen atom, etc.; and U.sup.K1, V.sup.K1, and S.sup.K1 each represent a methine group, etc.:

##STR00001##

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. ##STR00001##